drugset
drugset / Trial / NCT05009836

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

NCT05009836 ↗

Phase 3 Active not recruiting 412 enrolled Hutchmed
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Timeline

Start
2021-09-06
Primary completion
2028-05-30
Completion
2028-05-30

Outcome

Met primary endpoint

release “improvement in progression-free survival (PFS) versus Tagrisso alone” hutch-med.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Savolitinib Small molecule 200 mg Oral
Subject Savolitinib Small molecule 300 mg Oral
Subject Savolitinib Small molecule 400 mg Oral
Subject Savolitinib Small molecule 600 mg Oral
Background Osimertinib Small molecule 80 mg Oral

Indications

non-small cell lung carcinoma